Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: A pilot study

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Simone, Nicole L ^a   Soule, Benjamin P ^a   Gerber, Lynn ^b   Augustine, Elizabeth ^b   Smith, Sharon ^a   Altemus, Rosemary M ^a   Mitchell, James B ^a   Camphausen, Kevin A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FIBROSIS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; RADIATION INJURY; RADIOTHERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FIBROSIS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDONES; RADIATION INJURIES; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 34250637153     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-19     Document Type: Article

References (38)

1. O'Sullivan B Levin W Late radiation-related fibrosis: Pathogenesis, manifestations, and current management Semin Radiat Oncol 2003 13 3 274-289 10.1016/S1053-4296(03)00037-7 12903016
2. Hom DB Adams GL Monyak D Irradiated soft tissue and its management Otolaryngol Clin North Am 1995 28 5 1003-1019 8559569
3. Davis AM Dische S Gerber L Saunders M Leung SF O'Sullivan B Measuring postirradiation subcutaneous soft-tissue fibrosis: State-of-the-art and future directions Semin Radiat Oncol 2003 13 3 203-213 10.1016/ S1053-4296(03)00022-5 12903010
4. Delanian S Martin M Bravard A Luccioni C Lefaix JL Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage Radiother Oncol 2001 58 3 325-331 10.1016/S0167-8140(00)00332-7 11230895
5. Hallahan DE Haimovitz-Friedman A Kufe DW Fuks Z Weichselbaum RR The role of cytokines in radiation oncology Important Adv Oncol 1993 71-80 8505057
6. Neta R Okunieff P Cytokine-Induced Radiation Protection and Sensitization Semin Radiat Oncol 1996 6 4 306-320 10.1016/ S1053-4296(96)80026-9 10717188
7. Anscher MS Murase T Prescott DM Marks LB Reisenbichler H Bentel GC Spencer D Sherouse G Jirtle RL Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis Int J Radiat Oncol Biol Phys 1994 30 3 671-676 7928499
8. Anscher MS Kong FM Murase T Jirtle RL Short communication: Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF beta Br J Radiol 1995 68 807 331-333 7735779
9. McBride WH Cytokine cascades in late normal tissue radiation responses Int J Radiat Oncol Biol Phys 1995 33 1 233-234 10.1016/ 0360-3016(95)02019-8 7642425
10. Li M Jendrossek V Belka C The role of PDGF in radiation oncology Radiat Oncol 2007 2 5 1780053 17217530 10.1186/1748-717X-2-5
11. Okunieff P Augustine E Hicks JE Cornelison TL Altemus RM Naydich BG Ding I Huser AK Abraham EH Smith JJ Coleman N Gerber LH Pentoxifylline in the treatment of radiation-induced fibrosis J Clin Oncol 2004 22 11 2207-2213 10.1200/JCO.2004.09.101 15169810
12. Chiao TB Lee AJ Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis Ann Pharmacother 2005 39 3 516-522 10.1345/ aph.1E186 15701781
13. Gothard L Cornes P Brooker S Earl J Glees J Hall E Peckitt C Tait D Yarnold J Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy Radiother Oncol 2005 75 3 334-341 10.1016/j.radonc.2005.02.002 16086914
14. Delanian S Porcher R Balla-Mekias S Lefaix JL Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis J Clin Oncol 2003 21 13 2545-2550 10.1200/JCO.2003.06.064 12829674
15. Raghu G Johnson WC Lockhart D Mageto Y Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study Am J Respir Crit Care Med 1999 159 4 Pt 1 1061-1069 10194146
16. Gahl WA Brantly M Troendle J Avila NA Padua A Montalvo C Cardona H Calis KA Gochuico B Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome Mol Genet Metab 2002 76 3 234-242 10.1016/ S1096-7192(02)00044-6 12126938
17. Mesa RA Tefferi A Elliott MA Hoagland HC Call TG Schroeder GS Yoon SY Li CY Gray LA Margolin S Hook CC A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia Br J Haematol 2001 114 1 111-113 10.1046/j.1365-2141.2001.02883.x 11472354
18. Krupp LB LaRocca NG Muir-Nash J Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus Arch Neurol 1989 46 10 1121-1123 2803071
19. Winstead-Fry P Psychometric assessment of four fatigue scales with a sample of rural cancer patients J Nurs Meas 1998 6 2 111-122 10028778
20. Fix A Human Activity Profile: Professional Manual Odessa, Florida, Psychological Assessment Resources Inc 1988
21. Mahler DA Wells CK Evaluation of clinical methods for rating dyspnea Chest 1988 93 3 580-586 3342669
22. Tait RC Pollard CA Margolis RB Duckro PN Krause SJ The Pain Disability Index: Psychometric and validity data Arch Phys Med Rehabil 1987 68 7 438-441 3606368
23. Tait RC Chibnall JT Krause S The Pain Disability Index: Psychometric properties Pain 1990 40 2 171-182 10.1016/0304-3959(90)90068-O 2308763
24. Ware JE Jr. Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 1992 30 6 473-483 10.1097/00005650-199206000-00002 1593914
25. Herskind C Bentzen SM Overgaard J Overgaard M Bamberg M Rodemann HP Differentiation state of skin fibroblast cultures versus risk of subcutaneous fibrosis after radiotherapy Radiother Oncol 1998 47 3 263-269 10.1016/S0167-8140(98)00018-8 9681889
26. Johansen J Bentzen SM Overgaard J Overgaard M Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy Int J Radiat Biol 1994 66 4 407 412 7930844
27. Nieder C Zimmermann FB Adam M Molls M The role of pentoxifylline as a modifier of radiation therapy Cancer Treat Rev 2005 31 6 448-455 10.1016/ j.ctrv.2005.07.007 16225996
28. Lefaix JL Delanian S Vozenin MC Leplat JJ Tricaud Y Martin M Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: An experimental study Int J Radiat Oncol Biol Phys 1999 43 4 839 847 10.1016/S0360-3016(98)00419-2 10098440
29. Abdollahi A Li M Ping G Plathow C Domhan S Kiessling F Lee LB McMahon G Grone HJ Lipson KE Huber PE Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 2005 201 6 925-935 10.1084/jem.20041393 15781583
30. Iyer SN Gurujeyalakshmi G Giri SN Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 1999 291 1 367-373 10490926
31. Spond J Case N Chapman RW Crawley Y Egan RW Fine J Hey JA Kreutner W Kung T Wang P Minnicozzi M Inhibition of experimental acute pulmonary inflammation by pirfenidone Pulm Pharmacol Ther 2003 16 4 207-214 10.1016/S1094-5539(03)00026-9 12850123
32. Kaneko M Inoue H Nakazawa R Azuma N Suzuki M Yamauchi S Margolin SB Tsubota K Saito I Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts Clin Exp Immunol 1998 113 1 72-76 10.1046/j.1365-2249.1998.00618.x 9697986
33. Kehrer JP Margolin SB Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice Toxicol Lett 1997 90 2-3 125 132 10.1016/ S0378-4274(96)03845-3 9067480
34. Iyer SN Wild JS Schiedt MJ Hyde DM Margolin SB Giri SN Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters J Lab Clin Med 1995 125 6 779-785 7539478
35. Garcia L Hernandez I Sandoval A Salazar A Garcia J Vera J Grijalva G Muriel P Margolin S Armendariz-Borunda J Pirfenidone effectively reverses experimental liver fibrosis J Hepatol 2002 37 6 797-805 10.1016/ S0168-8278(02)00272-6 12445421
36. Suga H Teraoka S Ota K Komemushi S Furutani S Yamauchi S Margolin S Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats Exp Toxicol Pathol 1995 47 4 287-291 8855123
37. Azuma A Nukiwa T Tsuboi E Suga M Abe S Nakata K Taguchi Y Nagai S Itoh H Ohi M Sato A Kudoh S Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2005 171 9 1040 1047 10.1164/rccm.200404-571OC 15665326
38. Nagai S Hamada K Shigematsu M Taniyama M Yamauchi S Izumi T Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis Intern Med 2002 41 12 1118-1123 12521199